Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction.
OBJECTIVE
The effects of resveratrol treatment on ventricular arrhythmia, survival, and late cardiac remodeling were evaluated in rats with myocardial infarction (MI).


METHODS
Three groups of rats (S: ham-operated, MI, and MI pre-treated with resveratrol) were treated in an in vivo MI model by ligation of left anterior descending coronary artery. The electrocardiogram signals were monitored and recorded for 24 h using an implanted telemetry transmitter. The incidence of ventricular arrhythmias during the first 24-h after MI was also evaluated. Meanwhile, invasive in vivo electrophysiology with pacing in the right ventricle was performed in each group to assess the inducibility of ventricular arrhythmias.


RESULTS
Administration of resveratrol significantly suppressed the MI-induced ventricular tachycardia and ventricular fibrillation (0.4 +/- 0.2 in Resv group vs. 7.1 +/- 2.2 in MI group episodes per hour per rat, P < 0.01). Data also showed that the incidence of inducible ventricular tachycardia was lower in the Resv group than the MI group (46% vs. 81%, P < 0.01). The infarct size and mortality in the Resv group at 14 weeks were reduced by 20% and 33%, respectively, compared with the MI groups. Results from patch clamp recording revealed that resveratrol inhibited L-type calcium current (I (Ca-L)), and selectively enhanced ATP-sensitive K(+) current (I (K,ATP)) in a concentration-dependent manner.


CONCLUSIONS
These results suggested that the emerging anti-arrhythmic character induced by resveratrol treatment in rat hearts could be mainly accounted for by inhibition of I (Ca-L) and enhancement of I (K,ATP). Administration of resveratrol also improved the long-term survival by suppressing left ventricular remodeling.
Department of Cardiology, The Second Affiliated Hospital to Medical College, Shantou University, Shantou 515041, People's Republic of China.
You-Ren
YR
Chen
Fang-Fang
FF
Yi
Xin-Yi
XY
Li
Cheng-Yao
CY
Wang
Li
L
Chen
Xin-Chun
XC
Yang
Pi-Xiong
PX
Su
Jun
J
Cai
D000284:Administration, Oral; D000818:Animals; D020746:Calcium Channels, L-Type / Q000187:drug effects; D002304:Cardiac Pacing, Artificial / Q000379:methods; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004562:Electrocardiography; D054086:KATP Channels / Q000187:drug effects; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D018408:Patch-Clamp Techniques; D019736:Prostheses and Implants; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D012717:Sesquiterpenes; D013267:Stilbenes / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D015996:Survival Rate; D017180:Tachycardia, Ventricular / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D013686:Telemetry; D013729:Terpenes / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000188:drug therapy; D020257:Ventricular Remodeling / Q000187:drug effects / Q000502:physiology; D000094162:Phytoalexins
D020746:Calcium Channels, L-Type; D054086:KATP Channels; D012717:Sesquiterpenes; D013267:Stilbenes; D013729:Terpenes; D000077185:Resveratrol; D000094162:Phytoalexins